Tecan Group AG

LSE:0QLN Stock Report

Market Cap: CHF 2.3b

Tecan Group Valuation

Is 0QLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 0QLN (CHF187.39) is trading below our estimate of future cash flow value (CHF204.22)

Significantly Below Future Cash Flow Value: 0QLN is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QLN?

Key metric: As 0QLN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0QLN. This is calculated by dividing 0QLN's market cap by their current revenue.
What is 0QLN's PS Ratio?
PS Ratio2.7x
SalesCHF 882.48m
Market CapCHF 2.34b

Price to Sales Ratio vs Peers

How does 0QLN's PS Ratio compare to its peers?

The above table shows the PS ratio for 0QLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
ONT Oxford Nanopore Technologies
5x17.02%UK£1.1b
DXRX Diaceutics
3x18.33%UK£115.6m
HVO hVIVO
1.1x7.61%UK£53.2m
IXI IXICO
2.5x13.95%UK£18.0m
0QLN Tecan Group
2.7x4.77%CHF 2.3b

Price-To-Sales vs Peers: 0QLN is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (2.9x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 0QLN's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
0QLN 2.7xIndustry Avg. 3.3xNo. of Companies7PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0QLN is good value based on its Price-To-Sales Ratio (2.7x) compared to the European Life Sciences industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is 0QLN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QLN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.7x
Fair PS Ratio3.8x

Price-To-Sales vs Fair Ratio: 0QLN is good value based on its Price-To-Sales Ratio (2.7x) compared to the estimated Fair Price-To-Sales Ratio (3.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 187.39
CHF 175.48
-6.36%
14.32%CHF 220.00CHF 142.00n/a8
Jul ’27CHF 173.70
CHF 171.98
-0.99%
14.02%CHF 208.00CHF 138.00n/a8
Jun ’27CHF 155.90
CHF 165.48
+6.14%
12.66%CHF 205.00CHF 136.00n/a8
May ’27CHF 117.70
CHF 165.73
+40.80%
12.62%CHF 205.00CHF 136.00n/a8
Apr ’27CHF 136.09
CHF 167.10
+22.79%
11.53%CHF 205.00CHF 137.00n/a8
Mar ’27CHF 135.29
CHF 173.38
+28.15%
12.24%CHF 205.00CHF 137.00n/a8
Feb ’27CHF 136.35
CHF 197.33
+44.72%
34.81%CHF 384.00CHF 142.00n/a9
Jan ’27CHF 128.00
CHF 192.57
+50.44%
37.25%CHF 384.00CHF 124.10n/a9
Dec ’26CHF 138.60
CHF 202.48
+46.09%
34.77%CHF 384.00CHF 158.00n/a8
Nov ’26CHF 145.81
CHF 205.98
+41.26%
33.32%CHF 384.00CHF 160.00n/a8
Oct ’26CHF 148.37
CHF 220.64
+48.72%
29.58%CHF 384.00CHF 166.80n/a9
Sep ’26CHF 165.06
CHF 220.47
+33.57%
29.67%CHF 384.00CHF 165.20n/a9
Aug ’26CHF 162.15
CHF 225.02
+38.77%
28.05%CHF 384.00CHF 165.20n/a9
Jul ’26CHF 159.93
CHF 227.13
+42.02%
27.44%CHF 384.00CHF 165.20CHF 173.709
Jun ’26CHF 165.33
CHF 239.29
+44.74%
26.74%CHF 384.00CHF 188.00CHF 155.907
May ’26CHF 157.34
CHF 250.29
+59.08%
23.31%CHF 384.00CHF 192.00CHF 117.707
Apr ’26CHF 163.90
CHF 250.29
+52.71%
23.31%CHF 384.00CHF 192.00CHF 136.097
Mar ’26CHF 195.00
CHF 271.67
+39.32%
20.13%CHF 384.00CHF 225.00CHF 135.296
Feb ’26CHF 236.00
CHF 283.83
+20.27%
17.95%CHF 384.00CHF 230.00CHF 136.356
Jan ’26CHF 201.40
CHF 284.86
+41.44%
15.61%CHF 384.00CHF 241.00CHF 128.007
Dec ’25CHF 210.20
CHF 286.14
+36.13%
15.64%CHF 384.00CHF 241.00CHF 138.607
Nov ’25CHF 220.20
CHF 295.29
+34.10%
15.52%CHF 384.00CHF 241.00CHF 145.817
Oct ’25CHF 276.00
CHF 348.75
+26.36%
10.99%CHF 415.00CHF 300.00CHF 148.378
Sep ’25CHF 284.40
CHF 351.71
+23.67%
11.41%CHF 415.00CHF 300.00CHF 165.067
Aug ’25CHF 327.20
CHF 385.71
+17.88%
8.23%CHF 415.00CHF 330.00CHF 162.157
Jul ’25CHF 302.20
CHF 396.57
+31.23%
5.78%CHF 418.00CHF 347.00CHF 159.937
CHF 175.93
Fair Value
6.5% overvalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/30 05:28
End of Day Share Price 2026/07/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tecan Group AG is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harry GillisBerenberg
Delphine Le LouetBernstein
Susannah LudwigBernstein